10-Q: NRx Pharma Q2 Loss Widens Amid Funding Concerns

NRx Pharmaceuticals reported a significantly wider net loss in Q2 2025 and raised substantial doubt about its ability to continue as a going concern, despite advancing key drug candidates and clinic acquisitions.

Summary

• Net loss for the three months ended June 30, 2025, was $17.58 million, a significant increase from $7.90 million for the same period in 2024.
• Net loss for the six months ended June 30, 2025, was $23.09 million, compared to $14.43 million for the six months ended June 30, 2024.
• Accumulated deficit reached $301.37 million as of June 30, 2025.
• Total stockholders' deficit was $35.62 million as of June 30, 2025, worsening from $23.22 million at December 31, 2024.
• Working capital deficit increased to $35.86 million as of June 30, 2025, from $18.56 million at December 31, 2024.
• Cash and cash equivalents increased to $2.91 million as of June 30, 2025, from $1.44 million at December 31, 2024.
• Research and development expenses decreased to $0.99 million for Q2 2025 (from $2.80 million in Q2 2024) and $1.79 million for H1 2025 (from $4.55 million in H1 2024) due to conclusion of a Phase 2 study and cash conservation.
• General and administrative expenses decreased to $2.74 million for Q2 2025 (from $4.25 million in Q2 2024) and $5.69 million for H1 2025 (from $8.50 million in H1 2024).
• Incurred significant non-cash losses from changes in fair value of convertible note payable ($5.57 million in Q2 2025) and warrant liabilities ($6.41 million in Q2 2025).
• Recognized a loss of $1.87 million on convertible note conversions in Q2 2025.
• Filed an Abbreviated New Drug Application (ANDA) for NRX-100 (preservative-free intravenous ketamine) in Q2 2025 and received a first response on August 13, 2025.
• Expected to complete a New Drug Application (NDA) for NRX-100 in September 2025, with an anticipated FDA decision by year-end 2025.
• Initiated an NDA filing for NRX-101, with an anticipated FDA decision in Q1 2026.
• HOPE Therapeutics, Inc. is progressing with acquisitions of Dura Medical, NeuroSpa TMS, Cohen and Associates, LLC, and Kadima Neuropsychiatry Institute to establish interventional psychiatry clinics.

Sentiment

Score: 3

Explanation: While the company has made significant progress in drug development (Fast Track, Breakthrough Therapy designations, NDA filings) and strategic expansion into clinic operations, these positives are heavily overshadowed by severe financial distress. The substantial widening of net losses, increasing accumulated and working capital deficits, and an explicit 'going concern' warning indicate a highly precarious financial position and significant reliance on future dilutive financing. The financial instability outweighs the promising clinical and strategic developments in the short to medium term.

Positives

• NRX-100 received an expanded Fast Track Designation from the FDA for all indications and types of depression and related disorders, potentially expanding the addressable market to 13 million Americans.
• NRX-100's Fast Track Designation includes a specific finding that it addresses an unmet medical need, qualifying it for the Commissioners National Priority Voucher Program (CNPV), which could significantly reduce review time.
• NRX-100 received a filing fee waiver from the FDA, saving approximately $4.3 million.
• Submitted stability data for NRX-100 to the FDA, sufficient to support three years of room temperature shelf stability.
• Filed a patent application for NRX-100, the proprietary preservative-free formulation of intravenous ketamine.
• NRX-101 was previously awarded Breakthrough Therapy Designation by the FDA, facilitating development and expediting review.
• NRX-101 demonstrated a statistically significant reduction in akathisia in a Phase 2b/3 trial, a key safety endpoint.
• HOPE Therapeutics executed definitive purchase agreements for Dura Medical and a binding letter of intent for NeuroSpa TMS, and a binding letter of intent to acquire a 49% interest in Cohen and Associates, LLC.
• HOPE Therapeutics received approval pending legal stipulations for $7.8 million of debt financing to support clinic acquisitions.
• HOPE Therapeutics executed a non-binding term sheet for a strategic investment from a global medical device manufacturer.
• Cash and cash equivalents increased to $2.91 million at June 30, 2025, from $1.44 million at December 31, 2024.

Negatives

• Net loss significantly widened to $17.58 million for Q2 2025 from $7.90 million for Q2 2024, and to $23.09 million for H1 2025 from $14.43 million for H1 2024.
• Accumulated deficit increased to $301.37 million as of June 30, 2025.
• Total stockholders' deficit worsened to $35.62 million as of June 30, 2025.
• Working capital deficit substantially increased to $35.86 million as of June 30, 2025.
• The company concluded that substantial doubt exists regarding its ability to continue as a going concern for at least twelve months from the issuance date of the financial statements.
• Total current liabilities significantly increased to $40.45 million as of June 30, 2025, from $21.86 million at December 31, 2024.
• Incurred large non-cash losses from changes in fair value of convertible note payable ($5.57 million in Q2 2025) and warrant liabilities ($6.41 million in Q2 2025).
• Recognized a loss of $1.87 million on convertible note conversions in Q2 2025.
• The Alvogen License Agreement was terminated by Alvogen, resulting in a $4.7 million refund liability.
• Activities surrounding the Urinary Tract Infection (UTI) and chronic pain development programs are on hold into 2026 to focus on nearer-term programs.

Risks

• Substantial doubt exists regarding the ability to continue as a going concern, dependent on securing additional equity and/or debt financing.
• Additional equity financing could result in significant dilution to existing shareholders.
• Inability to refinance existing debt obligations could negatively impact business and operations.
• Projections for operating revenue from HOPE subsidiary and pharmaceutical products are subject to completion of anticipated clinical acquisitions and regulatory approvals.
• The acquisition of Kadima Neuropsychiatry Institute has not yet closed, and there is no assurance it will be consummated or provide anticipated benefits.
• Acquisitions may lead to unforeseen operational challenges and liabilities.
• The company is subject to risks common to the pharmaceutical industry, including new technological innovations by competitors, dependence on key personnel, reliance on third-party manufacturers, protection of proprietary technology, and compliance with regulatory requirements.
• Estimates used in financial statements, such as fair value of convertible notes and warrants, and stock-based compensation, involve inherent uncertainties and may differ materially from actual results.

Future Outlook

The company expects to continue incurring operating losses through the remainder of 2025. It projects operating revenue from its HOPE subsidiary clinics and pharmaceutical product sales in 2025, contingent on completing anticipated clinical acquisitions and obtaining regulatory approvals. The company anticipates FDA decision dates for its NRX-100 NDA potentially by year-end 2025 and for its NRX-101 NDA by the first quarter of 2026. It plans to pursue additional equity or debt financing or refinancing opportunities in 2025 and 2026 to fund ongoing clinical activities, meet debt obligations, and for general corporate purposes. The company intends to seek Accelerated Approval for both NRX-100 and NRX-101 and is initiating an expanded-access protocol for NRX-101 with TMS, organizing a Phase 2b/3 trial to confirm findings.

Management Comments

• Managements plan, through the establishment of HOPE, is to transform NRx from a pre-revenue biotechnology company to a revenue-generating enterprise that continues to develop life-saving drugs and technologies through NeuroRx, while also treating patients through HOPE.
• The Company has secured operating capital that it anticipates as sufficient to fund its drug development operations through year end and to finance submission of FDA New Drug Applications for NRX-100 and NRX-101.
• Management believes that the guidance received by the FDA [for NRX-100 ANDA] is a routine part of the regulatory process, provides a clear path to market for preservative-free ketamine, and will not result in any undue delay.
• Management believes that NRX-100 meets all five criteria [for the Commissioners National Priority Voucher Program].
• The Company believes that these data [for NRX-100] are sufficient for an FDA grant of initial market access subject to confirmatory data.
• NRX-101 is the only oral medicine that has ever been demonstrated in two randomized trials to reduce active suicidality and akathisia, to the Companys knowledge.
• Although no assurances can be given, and assuming we're able to consummate the proposed financings, management believes that we will have sufficient financing to consummate our previously announced acquisitions, execute our business plan and achieve our projected revenue objectives.

Industry Context

The company operates in the clinical-stage biopharmaceutical sector, focusing on central nervous system disorders, particularly those modulating the N-methyl-D-aspartate (NMDA) receptor. Its lead drug candidate, NRX-100 (IV ketamine), targets a market where intravenous ketamine is becoming a standard of care for acute suicidal depression, contrasting with intranasal Esketamine (SPRAVATO) which is not approved for suicidality or bipolar depression. The company's efforts to secure Fast Track and Breakthrough Therapy Designations align with FDA initiatives to expedite drugs for unmet medical needs. The establishment of HOPE Therapeutics positions the company to enter the medical care delivery market for interventional psychiatry, addressing a growing demand for comprehensive mental health treatments. Additionally, the company is exploring NRX-101's potential in treating antibiotic-resistant urinary tract infections (UTI) and urosepsis, a critical area given increasing antibiotic resistance, and its unique advantage of not compromising the intestinal microbiome, unlike common antibiotics.

Comparison to Industry Standards

• NRX-101 demonstrated a statistically significant reduction in akathisia in its Phase 2b/3 trial, with a 76% relative mean difference compared to lurasidone, and an akathisia level (2%) comparable to the placebo arm of the lurasidone registration trial.
• NRX-100's efficacy data from licensed trials show rapid and statistically significant reduction in suicidal ideation and depression, with one trial demonstrating non-inferiority to Electroconvulsive Therapy (ECT) on depression over a six-month period.
• The generic ketamine market is estimated at $750 million, while the innovative ketamine-based drug market (e.g., SPRAVATO) reported $1.3 billion in 2024 sales, indicating significant market potential for NRX-100.
• NRX-101's ability to not compromise the intestinal microbiome, unlike common antibiotics such as Clindamycin and Ciprofloxacin, positions it uniquely in the treatment of complicated Urinary Tract Infections (cUTI) if documented in human patients.

Management Changes

Legal Proceedings

• The company is involved in ongoing discussions regarding the closing of the acquisition of Kadima Neuropsychiatry Institute, with parties exploring either closing per the agreement terms or mutually agreeable alternative outcomes.
• The company is, from time to time, involved in various legal proceedings incidental to the conduct of its business, which historically have not had a material adverse effect.

Related Party Transactions

• Payments made to Glytech, LLC (owned by co-founder and former director Daniel Javitt) for ongoing scientific support and reimbursement of patent expenses.
• Compensation paid to Dr. Jonathan Javitt (Chief Scientist, major shareholder, and Board member) under a Consulting Agreement, totaling $0.3 million for Q2 2025 and $0.6 million for H1 2025.
• Compensation paid to Zachary Javitt (son of Dr. Jonathan Javitt) for website, IT, and marketing support, totaling less than $0.1 million for Q2 2025 and $0.1 million for H1 2025.
• Accrued annual discretionary bonus of $0.2 million for Dr. Jonathan Javitt as of June 30, 2025, and December 31, 2024.
• As of June 30, 2025, $0.2 million was included in accounts payable due to related parties.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing equity raises and potential future capital raises, alongside substantial accumulated deficits and a 'going concern' warning, which could negatively impact share value.
• Employees' job security is tied to the company's ability to secure ongoing financing to fund operations.
• Patients may benefit from the potential development and approval of new therapeutics for central nervous system disorders (NRX-100, NRX-101) and antibiotic-resistant infections, as well as expanded access to interventional psychiatry clinics through HOPE Therapeutics.
• Creditors face increased risk due to the company's substantial liabilities, widening losses, and the 'going concern' warning, which indicates uncertainty about the company's ability to meet its financial obligations.
• Suppliers and vendors may face payment risks given the company's financial condition and reliance on future financing.

Next Steps

• Respond to FDA comments and resubmit the Abbreviated New Drug Application (ANDA) for NRX-100.
• Complete the New Drug Application (NDA) for NRX-100, expected in September 2025.
• Await anticipated FDA decision dates for NRX-100 (year-end 2025) and NRX-101 (Q1 2026).
• Continue preparing the NDA for NRX-101, including submission of Module 3 manufacturing data.
• Pursue additional equity or debt financing or refinancing opportunities in 2025 and 2026.
• Consummate the proposed acquisitions for HOPE Therapeutics clinics (Dura Medical, NeuroSpa TMS, Cohen and Associates, Kadima Neuropsychiatry Institute).
• Negotiate with commercial lenders for additional financing to support clinic acquisitions.
• Initiate an expanded-access protocol for NRX-101 in combination with Transcranial Magnetic Stimulation (TMS).
• Organize a Phase 2b/3 randomized clinical trial to confirm the findings of NRX-101 with TMS.
• Apply for a PDUFA fee waiver from the FDA for NRX-101 based on public health need.
• Conduct confirmatory research for NRX-101 as required post-Accelerated Approval.
• Consider developing a follow-on product for Urinary Tract Infection (UTI) if NRX-101 succeeds in clinical trials.

Key Dates

Recommendation

The company's financial health is severely distressed, as evidenced by a significantly widening net loss, a substantial accumulated deficit, and a working capital deficit that has nearly doubled in six months. The explicit 'going concern' warning indicates a high risk of insolvency without further capital. While there are promising clinical and regulatory advancements for its drug candidates and strategic moves into clinic acquisitions, these long-term potentials are overshadowed by immediate and severe financial instability. The heavy reliance on future dilutive equity raises or debt, coupled with significant non-cash losses from fair value adjustments, suggests continued volatility and potential erosion of shareholder value. A seasoned investor would prioritize the acute financial risks over the speculative future upside.

Keywords

Biopharmaceutical, Clinical-stage, CNS disorders, Suicidal depression, Ketamine, NRX-100, NRX-101, FDA approval, ANDA, NDA, Fast Track Designation, Breakthrough Therapy Designation, HOPE Therapeutics, Psychiatry clinics, Going concern, Capital raise, Warrants, Convertible notes